Title: 1 Rapid and modular workflows for same-day sequencing-based detection of bloodstream 2 3 infections and antimicrobial resistance determinants 4 Authors: Mohammad Saiful Islam Sajib¹, Katarina Oravcova¹, Kirstyn Brunker^{1,2}, Paul Everest¹, Manuel 5 Fuentes¹, Catherine Wilson³, Michael E. Murphy^{3,4}, Taya Forde¹ 6 7 Affiliations: ¹School of Biodiversity, One Health & Veterinary Medicine, University of Glasgow, Glasgow, 8 9 United Kingdom ²MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom 10 ³Department of Microbiology, NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, New 11 Lister Building, Alexandra Parade, Glasgow, UK 12 ⁴School of Medicine, Dentistry & Nursing, College of Medical, Veterinary & Life Sciences, 13 Wolfson Medical School Building, University of Glasgow, Glasgow, UK 14 Keywords: 15 rapid diagnosis, selective host depletion, chemical host depletion, metagenomic next 16 17 generation sequencing, Oxford Nanopore technologies, selective sequencing, adaptive sampling, bloodstream infection, antimicrobial resistance 18 19 20 21 22 23 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

Background: Bloodstream infections (BSI) are a major global health concern, and existing diagnostic methods are too slow to guide targeted antibiotic therapy for critically ill patients, risking poor clinical outcomes. Rapid metagenomic-sequencing (mNGS) can facilitate swift pathogen and antimicrobial resistance (AMR) detection, but identification is challenged by significant host versus bacterial DNA in blood. To accelerate microbiological diagnosis, we developed M-15, a rapid and modular mNGS-based host DNA depletion workflow, validated with suspected BSI blood-culture samples and rapid culture-enriched spiked blood. Methods: To assess chemical host DNA depletion (CHDD) efficiency, M-15 was benchmarked with five commercial/published protocols. Later, M-15 was combined with rapid mNGS with/without adaptive sampling (AS) and tested on clinical blood-culture samples (n=33) from suspected BSI cases identified on BACT/ALERT VIRTUO (30 flagged positive, three remained negative). To determine whether it is possible to utilise M-15 mNGS prior to blood-culture flagging positive, a rapid enrichment method was tested starting with 1-10 colony forming units of the top 15 bacterial species causing BSI spiked into BACTEC medium enriched with 10 mL sheep blood. **Results:** All six chemical depletion protocols reduced host DNA by 2.5x10⁰ to 4.1x10⁶-fold, with the in-house M-15 protocol performing best, while adaptive sampling depleted host >5fold. With BACT/ALERT specimens, M-15 mNGS accurately identified 3/3 negative, 28/28 mono-bacterial, and 2/4 multi-bacterial species. With rapid culture-enrichment and M-15 mNGS, <18% DNA was classified as host and all bacterial species tested (n=10) were correctly identified. M-15 mNGS accurately predicted phenotypic AMR/susceptibility for 90.3% (232/257) of drug/bacteria combinations from BACT/ALERT positive samples. Conclusions: This study demonstrates that M-15 mNGS can facilitate species and AMR gene detection within 5-7 hours of BACT/ALERT positivity. Including 8-hour culture enrichment, microbiological and AMR confirmation is possible within 13-15 hours of sample collection. Thus, the M-15 mNGS workflow has the potential to improve patient outcomes in BSI.

Background

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

Bloodstream infection (BSI) is one of the leading causes of death worldwide, with 2.9 million cases each year [1]. Rapid identification of the causative bacterial pathogens and their antimicrobial resistance (AMR) profiles is crucial for guiding more effective treatment and better patient outcomes, especially for critically ill patients such as those who develop sepsis [2]. Blood culture, the gold standard diagnostic method, often takes 48-72 hours, which is too slow to guide targeted antibiotic therapy. This necessitates the prescription of empirical antibiotics, which may fail to cover the resistance profile of the causative pathogen and risk poor clinical outcomes [3]. Also, the use of broad-spectrum antibiotics to limit disease progression may disrupt beneficial gut microbiota and contribute to the development of multidrug-resistant bacteria often associated with healthcare infections, further limiting the reserve of critically important antimicrobial agents [4]. Thus, there is an urgent need for rapid diagnostic tools to better inform antibiotic regimens at the early stages of BSI. Certain applications of metagenomic next-generation sequencing (mNGS) could be used to rapidly identify bacterial species and AMR determinants, and therefore have the potential to accelerate BSI diagnosis [5]. However, the proportion of host DNA in blood compared to that of bacteria makes it challenging to directly sequence and generate adequate reads from the pathogen to accurately identify species and AMR in a cost-effective manner and within a clinically relevant timeframe. To address this issue, we developed a rapid mNGS-based chemical host DNA depletion (CHDD) protocol, named M-15, and compared its performance with two commercial kits (C1-2) and three published methods (P1-3) [6-8]. Next, M-15 mNGS was validated with and without nanopore adaptive sampling using both culture (BACT/ALERT an automated blood culture system) positive and negative enriched blood samples collected from patients with suspected BSI. Finally, M-15 was combined and tested with a rapid (8hour) culture (BACT/ALERT) enrichment step to reduce turnaround time and enable same-day microbiological diagnosis of bloodstream infections.

Methods

Bacterial strains and host matrix

Defibrinated sheep blood (E&O Laboratories, UK) and EDTA-treated whole blood from healthy

human volunteers were used as model host environment matrix. The list of clinical and/or

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

American Type Culture Collection (ATCC) strains tested/used in this study can be found in Tab. 1, S1, S2 and S3. Primers, probes, and amplification parameters To assess the depletion efficiency of the protocols, universal 16S rRNA, 18S rRNA and bacterial species-specific primers and probes were utilised [9-12]. The total volume of individual gPCR reactions was 20 µL, with 2x Rotor-Gene Multiplex PCR master mix (Qiagen, Hilden, Germany) and 2 μL DNA template. qPCR reactions were performed on a Rotor-Gene Q real-time cycler for up to 40 cycles (Qiagen, Hilden, Germany). The primer/probe sequences, concentrations and PCR cycling parameters are provided in Tab. S4. Benchmarking host depletion kits and protocols A chemical host DNA depletion protocol, named M-15, was developed in this study (Fig. 1, Supplement Protocol: M-15 mNGS) and benchmarked alongside two commercial [Zymo-HostZERO (named C1; Zymo Research, CA, USA), MolYsis-Complete5 (C2; Molzym GmbH & Co, Bremen, Germany)] and three published host depletion protocols P1 [6], P2 [8], and P3 [7]. To determine host depletion efficiency and analytical sensitivity of the workflows, serially diluted (100 to 105 CFU/mL) exponential growth phase cells of Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 25923), and Pseudomonas aeruginosa (ATCC 27853) strains were spiked in 400 µL sterile whole blood (human and sheep) and processed to deplete host cells/DNA with all the six protocols. Following host depletion with P1, P2, P3 and M-15, DNA extraction was performed using QIAamp UCP Pathogen Mini Kit (Qiagen, Hilden, Germany) with the recommended homogenisation step by bead beating (Pathogen Lysis Tubes L, Qiagen, Hilden, Germany). For protocols C1 and C2, DNA extraction was performed using the reagents supplied with the kits. Total DNA was extracted from the same spiked blood samples without host depletion similarly as unenriched (non-CHDD) controls. Extracted DNA was tested using qPCR with the 16S rRNA, 18S rRNA, and species-specific primers/probes described above. In addition, a subset of the simulated M-15 CHDD samples, containing 10⁴ to 10¹ CFU/mL

blood was extracted, amplified and barcoded for sequencing using ONT Rapid PCR barcoding

kit (SQK-RPB004; Oxford Nanopore technologies, Oxford, UK) and sequenced on MinION R9.4.1 flow cells. Live GPU basecalling was performed in high accuracy mode (dna r9.4.1 450bps hac) and passed Fastq reads were analysed using Chan Zuckerberg infectious diseases (CZ ID) (v0.7; https://czid.org/) Nanopore workflow (last accessed: 07/08/2024) [13].

113

114

115

116

117

118

119 120

121

122

123

124

125

126

127

128

129

130

131




Fig. 1: Schematic diagram depicting major steps involved in M-15 CHDD and mNGS workflow. Both BACTEC flagged positive and rapid enriched (8-hour), blood culture samples can be used as input. M-15 CHDD is the first step where host DNA is selectively depleted with saponin and DNase I treatment. Host depleted materal is then subjected to alkaline lysis and whole genome amplification with REPLI-g single cell kit. Amplified product is then debranced using T7 Endonuclease I and sequencing is performed with rapid barcoding (mid-low yield) or native barcoding (high-yield) kit.

Determining the contribution of host depletion on bacterial cell loss/viability

Bacterial cell loss and/or viability following host depletion was determined using E. coli, S. aureus, and P. aeruginosa ATCC strains. Approximately 30 and 3 CFU of the exponential phase cells were spiked in 400 µL sterile whole blood, and the samples were processed to deplete host DNA with three top performing protocols C1, C2, P1, and M-15. Host depleted samples were resuspended in PBS and plated on nutrient and blood agar media to estimate bacterial concentrations using the method described by Miles & Misra [14]. The same samples were

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

plated directly without host depletion as controls. All the inoculated plates were incubated overnight at 37°C, and the number of visible colonies was recorded the next day. Rapid M-15 mNGS workflow tested on culture enriched specimens To determine the efficiency of M-15 mNGS protocol on culture enriched samples, six culture enriched suspected BSI samples were tested initially. Three samples flagged positive on BACT/ALERT (bioMérieux, Marcy-l'Étoile, France) and the remaining three were reported to be culture negative. The same samples were processed directly without M-15 as no depletion controls. To minimise hands on time, rapid alkaline cell lysis was performed using 4 µL direct or host depleted samples resuspended in 1 mL PBS using REPLI-g single cell kit (Qiagen, Hilden, Germany). Multiple displacement amplification (MDA) was performed with the same kit for 60 minutes according to the manufacturer's recommendation. Amplified MDA products were then debranched for 10 minutes at 37° C using T7 endonuclease (New England Biolabs, MA, United States) and subjected to 0.5x AMPure bead cleanup. Library was prepared using ONT Rapid barcoding kit (SQK-RBK004) with 400 ng amplified debranched DNA product/sample as an input (Supplement Protocol: M-15 mNGS + low-medium yield protocol). The overall sample processing time of this pilot version of the workflow is approximately 4 hours (processing 6-10 samples), including 80 minutes for host depletion, 20 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLI-g Single Cell Kit, and 90 minutes for debranching, cleanup, library preparation and flow cell loading. To assess the efficiency of adaptive sampling (AS) with or without CHDD with M-15, rapid adapter ligated pooled libraries (six CHDD and six no CHDD) were loaded on a MinION R9.4.1 flow cell and the total number of channels (N= 512) available for sequencing were divided into two parts from the advanced option menu on the MinKNOW graphical user interface. Channels 1 to 256 were chosen for human DNA depletion using T2T-CHM13v2.0 as reference [15] and channels 257-512 for no-adaptive sampling control. High yield M-15 mNGS workflow validated with culture-positive suspected BSI specimens An additional 27 blood culture positive samples were tested using the optimised workflow for improved sequencing yield. Chemical host depletion, DNA extraction, MDA (60 minutes) and debranching were performed similarly to the pilot protocol. Only this time, library preparation

was performed using Ligation Sequencing Kit (SQK-LSK109) with native barcodes (EXP-

NBD104) with 400 ng amplified debranched DNA product/sample as an input (Supplement Protocol: M-15 mNGS + high yield protocol). The overall sample processing time of this optimised workflow takes less than 6 hours (with 6-10 samples) including 80 minutes of CHDD, 20 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLIg Single Cell Kit, and about 180 minutes for debranching, library preparation and loading.

To identify bacterial species, CZ ID pipeline was utilised as mentioned above with a 20% abundance cutoff (200,000 Base Per Million; BPM for CZ ID). Host-filtered contigs remaining after the 20% abundance cutoff were analysed to identify AMR determinants with ResFinder 4.5.0 [16] using the default options. In addition, host filtered fastq reads remaining after 20% abundance cutoff were mapped against bacterial reference sequences using minimap2[17] to estimate the breadth of coverage and sequencing depth. To determine the minimum sequencing yield required to identify bacterial species and AMR determinants, 100 Mbp, 50 Mbp, 40 Mbp, 30 Mbp, 20 Mbp, and 10 Mbp raw fastq reads were randomly subsampled using rasusa [18] and processed similarly with CZ ID and ResFinder.

Rapid culture enrichment to accelerate microbiological diagnosis

A shorter culture enrichment method was tested with 16 ATCC/clinical isolates representing eight Gram negative and seven Gram positive bacterial species. Approximately 1-10 CFU of actively growing (log phase) bacterial cells were spiked in BD BACTEC™ Standard Blood Culture media (Becton, Dickinson and Company, NJ, USA) supplemented with 10 mL sterile whole blood (sheep), and then subjected to incubation. Culture bottles were taken out at 2-hour intervals over a span of 10 hours and subsequently plated on nutrient and blood agar media using the Miles & Misra method.[14] All the plates were incubated at 37°C overnight and the number of visible colonies was recorded the next day. One mL culture-enriched samples were preserved at-80°C during each sampling session to be tested later. Finally, a subset (10/16) of the 8-hour culture-enriched samples (5 Gram-positive and 5 Gram-negative species) were chosen and processed with the high yield M-15 mNGS protocol (Supplement Protocol: M-15 mNGS + high yield protocol). Species, host: pathogen ratio, antimicrobial resistance genes and minimum DNA yield per sample for identification were determined using the same pipelines and cutoffs mentioned above.

Conventional tests for detecting species, AMR, and predicting AMR with sequencing

In the routine diagnostic microbiology laboratory, 5-10 mL EDTA treated blood samples collected from suspected individuals were incubated in the BACT/ALERT system for up to 5 days. Samples that flagged positive were taken out and inoculated onto appropriate agars, and organisms grown identified using MALDI-TOF mass spectrometry (Bruker Corporation, MA, USA). Phenotypic antimicrobial sensitivity was determined using disc diffusion as described by European Committee on Antimicrobial Susceptibility Testing (EUCAST) guideline [19] or automated systems, e.g. Vitek2 (bioMérieux, Marcy-l'Étoile, France).

To compare routine phenotypic sensitivity and genotypic antimicrobial susceptibility results, AST results for the BACT/ALERT positive BSI samples were compared to ResFinder 4.5.0 phenotype table results. Because ResFinder provides AMR predictions for 92 antimicrobial agents from 21 antibiotic classes, but only predicts resistance or susceptibility (not Intermediate results), only the phenotypic results common between the two (culture and sequencing) and classified as resistant or susceptible were compared. For rapid culture enriched spiked blood samples, for which AST results were not available, WGS (where available) and M-15 mNGS data of the ten ATCC/clinical isolates were compared similarly using ResFinder 4.5.0 phenotype table. Categorical agreement, major error and very major error were calculated using the following formula [20]:

212
$$Major error = \frac{FR}{FR + TS}$$

$$Very major error = \frac{FS}{FS + TR}$$

Where: TR = True resistant, TS = True susceptible, FR = False resistant, FS = False susceptible, and where phenotypic AST is taken as the gold standard.

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

species, possibly indicating similar lysis bias [20].

Statistical analysis R studio 2023.12.1 with R base version 4.3.3 were used in combination with readxl, dplyr, reshape2, ggplot2, and gridExtra packages for performing data cleanup, formatting, analysis and generating graphs. **Results** Chemical depletion protocols remove unwanted host with high efficiency Protocols M-15 and P1 removed 4.1×10⁶ (Quantification cycle ΔCt-20.52) and 5.5×10⁵ fold (ΔCt-17.45) host DNA, respectively, from the whole blood samples spiked with Escherichia coli, Staphylococcus aureus, or Pseudomonas aeruginosa ATCC strains, with depletion efficiency over 99.99%. Commercial kit C1 removed 99.82% (5.87×10^2 fold) host, and C2, 97.93% (4.84×10^1 fold). Approximately 81.09% and 59.19% host were removed with the protocols P2 and P3, respectively (Tab. 1). Between 5.58% (P3) and 51.63% (M-15) bacterial DNA were removed during host depletion with the six kits/protocols. Protocols with higher depletion efficiencies also exhibited increased bacterial DNA loss (Tab. 1). Protocol C2 exhibited a strong negative bias towards *P. aeruginosa*, as >99% (ΔCt -10.27) loss was observed, possibly due to the detrimental effect of buffer CM (a selective host cell lysis buffer provided in the kit) on this bacterial species during the host lysis steps. In a recent study, where blood culture positive samples were processed with protocol C2 to deplete host and enable rapid sequencing-based species and AMR identification [20] sequencing results also indicated suboptimal accuracy of C2 mNGS for P. aeruginosa compared to other bacterial

Tab. 1: Host depletion efficiency and bacterial DNA loss observed with in-house chemical host DNA depletion method, M-15, compared with two commercial kits (C1-2) and 3 published protocols (P1-3).

241

242

243

244

245

Organism	Methods/Kits	Ct (SD) No chemical depletion	Ct (SD) Chemical depletion	ΔCt	Fold Reduction	DNA Removal (%)	
Host depletion	efficiency						
Ovis aries	M-15 (this study)	16.24 (0.79)	36.76 (1.82)	-20.5	4.1×10 ⁶	99.99998%	
Ovis aries	P1 [6]	16.24 (0.79)	33.69 (0.99)	-17.5	5.5×10 ⁵	99.99982%	
Ovis aries	Zymo HostZero (C1)	20.30 (0.58)	29.74 (2.10)	-9.43	5.9×10 ²	99.82966%	
Ovis aries	Molysis Complete 5 (C2)	20.51 (0.64)	25.73 (1.08)	-5.2	4.8×10 ¹	97.93324%	
Ovis aries	P2 [7]	18.97 (0.49)	21.15 (0.53)	-2.2	5.3×10°	81.09315%	
Ovis aries	P3 [8]	18.97 (0.49)	20.15 (0.51)	-1.2	2.5×10°	59.19500%	
Bacterial loss							
E. coli	M-15 (this study)	23.69 (1.04)	23.91 (0.47)	-0.22	1.3×10°	23.87932%	
E. coli	P1 [6]	23.94 (0.43)	22.41 (0.22)	1.5 0.35		0.00%	
E. coli	Zymo HostZero (C1)	24.57 (0.34)	25.34 (0.65)	-0.8	1.6×10 ⁰	37.93000%	
E. coli	Molysis Complete 5 (C2)	23.73 (0.67)	23.27 (0.55)	0.5	0.74	0.00%	
E. coli	P2 [7]	22.18 (0.28)	28) 22.84 (0.73)		1.5×10°	31.14783%	
E. coli	P3 [8]	22.18 (0.28)	21.39 (0.24)	0.8	0.58	0.00%	
P. aeruginosa	M-15 (this study)	23.09 (0.46)	24.26 (0.66)	-1.2	2.1×10 ⁰	53.08692%	
P. aeruginosa	P1 [6]	21.84 (0.32)	23.53 (0.27)	-1.7	3.3×10°	69.37233%	
P. aeruginosa	Zymo HostZero (C1)	25.98 (0.23)	26.70 (0.17)	-0.7	1.7×10°	39.94829%	
P. aeruginosa	Molysis Complete 5 (C2)	25.03 (0.38)	35.31 (1.79)	-10.3	6.8×10 ²	99.85400%	
P. aeruginosa	P2 [7]	23.62 (0.46)	24.09 (0.23)	-0.5	1.4×10°	30.04768%	
P. aeruginosa	P3 [8]	23.56 (0.44)	23.43 (0.44)	0.1	0.92	0.00%	
S. aureus	M-15 (this study)	20.59 (1.15)	22.49 (0.32)	-1.9	4.5×10°	77.91082%	
S. aureus	P1 [6]	21.94 (1.06)	22.74 (0.40)	-0.8	2.0×10°	50.21738%	
S. aureus	Zymo HostZero (C1)	26.76 (0.62)	26.07 (0.27)	0.7	0.66	0.00%	
S. aureus	S. aureus Molysis Complete 5 (C2)		23.33 (0.61)	-0.6 1.4×10 ⁰		28.46943%	
S. aureus	S. aureus P2 [7]		23.46 (0.23)	23.46 (0.23) -0.7		38.07282%	
S. aureus	P3 [8]	22.78 (0.31)	23.04 (0.26)	-0.3	1.2×10 ⁰	16.75203%	

SD: Standard deviation, Ct: Cycle threshold, ΔCt: Difference in quantification cycle

CHDD protocols perform poorly with samples containing low bacterial concentrations

Although the host depletion efficiency of some of the protocols, including M-15 was encouraging, we observed some bacterial loss. Therefore, we aimed to evaluate their

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

applicability on blood samples with low bacterial concentrations (1 to 100 CFU/mL), as typically seen in BSI cases [21]. For this, we selected the top performing protocols, M-15, P1, C1 and C2, which exhibited the highest host depletion efficiency. For all three ATCC strains tested (E. coli, S. aureus, P. aeruginosa), qPCR analytical sensitivity of protocols M-15, P1 and C1 was 10² CFU/mL. With protocol C2, qPCR was able to detect up to 10¹ CFU/mL E. coli and S. aureus; however, like before, Ct values from P. aeruginosa spiked CHDD samples were consistently very high (Ct >30) across all five *P. aeruginosa* concentrations (10° to 10^{4} CFU/mL) spiked in whole blood (Fig. 2A). To understand which part (chemical wash or DNA extraction) of the CHDD protocols is contributing to reduced recovery of bacterial DNA, we processed low abundant spiked samples (<30 and <3 CFU/mL) with M-15, P1, C1 and C2 protocols and confirmed viability/recovery with culture. Viable plate counts following CHDD showed protocols C1 retained 92%, M-15 76% and P1 62% of bacteria of the low initial counts of <30 cells spiked in blood (Fig. 2B). With even lower concentration (<3 cells), the overall bacterial recovery rate with protocols C1, M-15, and P1 were 72%, 43% and 13% respectively compared to the no CHDD controls (Fig. 2B). No viable bacteria were recovered using protocol C2 for any of the bacterial species or samples tested; again, possibly indicating buffer CM's effect on their growth or viability, although P. aeruginosa was the only species (specifically ATCC 27853) tested in this study that displayed suboptimal performance with downstream molecular assays (Fig. 2B). In order to estimate the proportions of expected bacterial DNA (i.e., bacterial species spiked initially) versus host and others (unclassified and other species), a subset of simulated M-15 CHDD samples (highest host depletion efficiency; 4.1×10⁶ fold), having 10⁴ to 10¹ E. coli CFU/mL were sequenced. While the host: bacteria DNA ratio might differ between bacterial species due to the difference in their genome size, this would facilitate estimating the lowest bacterial concentration (CFU/mL) that would most likely provide consistent results with downstream molecular applications, especially sequencing. The proportion of expected bacterial (E. coli that were initially spiked) DNA sequence yield (mega base pairs; Mbp) in M-15 CHDD samples were 53.4% and 9.7% of total DNA for samples containing 10⁴ and 10³ CFU/mL bacteria respectively. For low abundant samples, bacteria represented only 1.1% (10² CFU/mL) and 0.2% (10¹ CFU/mL) of total DNA yield following >99.99% host removal with M-15 (Fig. 2C). Proportion of DNA sequence yield from expected bacterial species compared to the host remained unchanged throughout the sequencing run regardless of bacterial concentration spiked or DNA ratio (Fig. 2C). The suboptimal host: pathogen ratio in low abundant blood samples meant that sequencing-based assays may not yet provide satisfactory results even with CHDD, unless an additional enrichment/depletion step is included pre/post DNA extraction to further improve bacterial proportions, and a more robust and sensitive DNA extraction method is benchmarked and validated.

277

278

279

280

281

282

283

284 285

286

287

288

289 290

291

292

293

294

295

296




Fig. 2: Overall performance of M-15 versus published/commercial protocols (A) qPCR Ct values (median and standard deviation) of different concentrations (10^4 to 10^0 CFU/mL – see legend) of three ATCC strains (Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus) spiked in whole blood and processed with top chemical host DNA depletion (CHDD) kits/protocols (P1, M-15, C1, and, C2) performing the best in terms of host DNA depletion. (B) Number of viable cells recovered from blood samples spiked with <30 and <3 CFU of the three ATCC strains following CHDD with P1, M-15, C1, and, C2, compared to the no CHDD/PBS control. (C) Proportion of expected bacteria initially spiked in blood for M-15 CHDD, compared to host (sheep) DNA, other bacterial species (different from the three species spiked), and unclassified reads, over 16 hours of MinION sequencing. The four facets are showing simulated/spiked bacterial concentration ranging from 10⁴ to 10¹ CFU/mL of sheep blood.

M-15 mNGS and adaptive sampling significantly improve bacterial proportions

Due to suboptimal performance of M-15 mNGS observed with low bacterial concentrations directly in blood samples, three BACT/ALERT positive (BCP01-BCP03) and three negative

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

(BCN01-BCN03) culture enriched samples from suspected BSI cases were initially tested with a rapid version of M-15 CHDD protocol (Fig. 1). Length of the sequencing reads varied significantly among organisms, with expected bacterial species (species that were identified with culture-based methods) having the highest median read length (1,957 bp); this was 8.15x longer than the unclassified reads (240 bp), 3.52x longer than human reads (552 bp) and 1.7x longer than other bacterial reads (mixed bacterial species not expected from the sample; 1,145 bp) (Fig. 3A). The read length difference between host and bacteria could be the result of CHDD, as host DNA was digested with DNase I following selective lysis. Overall yield in the adaptive sampling (AS) channels (1-256) was 1.86x lower (550.33 Mbp AS vs 1023.72 Mbp no-AS) than no-AS (channels 257-512), although the total number of reads for AS and no-AS samples was almost the same, with 345,085 and 334,054 reads, respectively. Median read length for AS channels was 3.2x shorter than the no-AS, and host constituted >90% of the reads that were smaller than 1kb in AS channels (Fig. 3B). This illustrates that AS influenced the length of sequenced fragments as a result of its limited ability to deplete shorter host reads (≤1 Kbp), which were highly abundant in the directly extracted no-CHDD samples. Samples processed with M-15 CHDD had 1.14 ×10³ times less human DNA compared to the no CHDD controls (based on sequencing yield in Mbp; Fig. 3D). Samples sequenced using AS had 5.52-fold less human DNA compared to the controls; however, no bacterial enrichment was observed (Fig. 3C, 3D). This highlights the importance of host depletion even in positively flagged culture-enriched specimens, as it may lead to lower sequencing cost per sample, and more importantly, reduce the sequencing time required to reach a desired yield for determining the bacterial species responsible for the BSI.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.




Fig. 3: Host depletion efficiency of M-15 mNGS and adaptive sampling (AS), versus no chemical host DNA depletion (CHDD) and no AS, tested with patient samples (A) Violin plot showing size distribution of sequencing reads aligned to expected bacterial species, host (human), other bacterial species, and reads for which there were no matches within the blast Nr/Nt database. (B) Histogram highlighting the number of raw sequencings reads from expected bacteria, host, others (other bacteria or unclassified). Coloured facets subdividing the raw reads further to distinguish read length variation by AS, no AS and CHDD and no CHDD. (C) Overall sequencing yield of CHDD and no-CHDD samples sequenced, comparing AS and no-AS. Stacked coloured bars highlight the proportion of DNA aligned to host, bacteria and others/unclassified species (see legend). Blood culture positive (BCP) samples are shown in red text, while blood culture negative (BCN) samples are shown in black. (D) Depletion efficiency (fold difference, FD) in DNA yield (Mbp) of sequences from host with CHDD and AS compared to no-CHDD and no-AS.

M-15 mNGS accurately predicts mono-bacterial species in BACT/ALERT positive samples

Because suboptimal sequencing yield was observed when debranched M-15 CHDD Multiple Displacement Amplification (MDA) samples were initially processed (rapid M-15) using the rapid barcoding kit (**Fig. 1**), it was decided to utilise the Ligation sequencing kit with native

barcodes (Fig. 1). Additional 27 culture (BACT/ALERT) positive BSI blood samples were processed with the high-yield M-15 mNGS protocol. Overall, blood-culture positive (BCP) samples subjected to CHDD had 152.4x higher DNA concentration compared to culture negative (BCN) samples (BCP CHDD 509.02 ng/µL versus BCN CHDD 3.34 ng/μL, as measured using Qubit) after 60 minutes MDA (Fig. 4A, Tab. S1). However, directly extracted and amplified blood culture negative samples yielded 753 ng/µL DNA on average following 1-hour MDA with REPLI-g kit (Tab. S1). Four bacterial species with high GC content, Brevibacterium luteocum (GC 67.8%), Micrococcus luteus (GC 74.0%), Stenotrophomonas maltophilia (GC 66.7%) and Achromobacter xylosoxidans (GC 64.0%) yielded low DNA (15.7x less than other species), with an average of 32.23 ng/μL after 1-hour MDA; however, this was still 9.64x higher than BCN samples following CHDD (Tab. S1). The potential reason behind low yield in species with high GC%could involve stable secondary structure or denaturation difficulties as highlighted in some studies [22, 23]. With CZ ID, using a cutoff of 20% abundance (200,000 Bases Per Million: BPM) successfully removed all bacterial species identified except those detected using culture-based methods. Using this cutoff, sequencing correctly identified 28/28 mono-bacterial species, 3/3 negative samples and 2/4 multi-bacterial species found in two samples (Fig. 4B, S1 A). Initially, it was assumed that the two species (K. oxytoca and E. faecalis) in two mixed samples (BCP05, and BCP24) were missed due to bacterial cell lysis during CHDD (Fig. 4B). However, some of the mono-bacterial samples tested in this study contained the same bacterial genera/species and no negative bias was observed with sequencing following CHDD. Also, all the CHDD flagged positive samples (n=30, species=17) were cultured overnight to confirm viability, and only one (M. luteus) showed visible growth impairment on agar plates (Tab. S1). Therefore, it is likely that these two organisms were missed with sequencing due to their relatively low abundance compared to the other species present in the sample. For one sample (BCP15), Klebsiella pneumoniae was identified with culture but Klebsiella variicola with mNGS; however, the species was later confirmed to be K. variicola with 16S rRNA amplicon sequencing. Overall, expected bacterial species constituted 88.7% of total sequencing yield versus human which represented only 0.46% total DNA (Fig. 4B).

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.




Fig. 4: Species and antimicrobial resistance prediction accuracy of M-15 mNGS (A) DNA concentration (ng/μL) of three blood culture negative (BCN01-BCN03) and 30 blood culture flagged positive (BCP) samples, following M-15 chemical host DNA depletion (CHDD), and whole genome amplification with the REPLI-g kit. Quantification was performed with Qubit Broad Range dsDNA assay. (B) Proportion of expected bacterial DNA (yellow bar chart; confirmed by culture) versus all other reads following M-15 CHDD and MinION sequencing with native barcoding kit. BACT/ALERT positive samples that have species-level agreement with culture have text labelled dark blue, those with genus-level agreement are purple, and those not detected by sequencing are labled red. (C) Cumulative depth for eight Gram-positive and nine Gram-negative organisms from 30 BACT/ALERT positive blood culture samples following M-15 mNGS, with 100 Mbp sequencing yield per sample. (D) Number and proportion of true positive, true negative, false positive and false negative AMR predictions with M-15 mNGS compared to the standard culture-based AST prediction for 30 BACT/ALERT positive blood culture samples. (E) Number and proportion of ResFinder true positive, true negative, false positive, false positive, and false negative AMR predictions with M-15 mNGS by bacterial species

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

from the 30 BACT/ALERT positive blood culture samples tested in this study. (F) Number and proportion of true/false AMR predictions with mNGS for the same culture-positive samples categorised by antibiotics tested. Prediction of AMR profile with mNGS was done only using the resistance and susceptibility results from antibiotics that were present in both phenotypic and genotypic datasets (n=257). To understand the breadth of coverage across the bacterial genomes with 100 Mbp sequencing yield per CHDD sample, 100 Mbp fastq reads subsampled with rasusa were analysed. For every 100 Mbp DNA sequenced per sample, 96.76% and 99.48% coverage could be achieved with at least 1x depth for the Gram-positive and Gram-negative organisms tested, respectively. For 5x and 10x depth, Gram positive organisms had a mean genome coverage of 87.89% and 78.29% and Gram-negatives 95.28% and 78.38%, respectively (Fig. 4C). For all the 30-blood culture positive samples tested (BCP01 to BCP30), >20% abundance cutoff accurately identified the present bacterial species with as low as 10 Mbp sequencing yield per sample (Fig. S1 A). Rapid culture enrichment can facilitate same-day microbiological identification When a blood culture is flagged as positive, it contains approximately 10^7 to 10^9 bacterial cells/mL of culture broth[24], which is more than the input concentration (≥10⁴ CFU/mL) required for the M-15 mNGS to work reliably, as observed during our initial experiments (Fig. 2C). This meant that a shorter culture enrichment step could further accelerate the microbiological diagnosis, and M-15 mNGS could be utilised even before a sample flags positive. However, given the variety of bacterial species involved in BSI and differences in their growth rate, we aimed to understand the minimum incubation period required to reach that threshold with a representative range of clinically important bacterial species (n=15). Four of 15 bacterial species tested (Streptococcus agalactiae, Acinetobacter baumanii, Klebsiella pneumoniae and Escherichia coli) reached 10⁴ CFU/mL, the optimal concentration for M-15 mNGS, under 6 hours of culture enrichment (Fig. 5A). With 8-hour incubation, 12/15 species reached the desired threshold of 10⁴ CFU/mL. The remaining three species, Staphylococcus aureus, Streptococcus pneumoniae and Pseudomonas aeruginosa, were slightly lagging, reaching approximately 6.04x10³ CFU/mL on average with 8-hour enrichment. All the species (15/15) tested reached/crossed the threshold under 10 hours of culture enrichment (Fig. 5A).

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

To identify proportions of expected bacteria obtained using M-15 mNGS after 8-hour rapid culture enrichment, three sterile blood culture samples and a subset of 10 bacterial species (5 Gram positive and 5 Gram negative, including the three slow-growing species tested earlier) were selected and processed with this approach (Fig. 5A, C). One potential costly drawback with the rapid enrichment approach could be the necessity to blindly sequence all blood cultures if the positive and negative samples could not be differentiated prior to sequencing. However, following CHDD and 60 minutes of MDA, the rapid culture-enriched spiked blood samples (RESB, n=10) showed 28.16x higher dsDNA concentration (154.6 versus 5.49 ng/μL) on average compared to sterile human blood enriched as negative controls (SBC, n=3), providing a unique signature for the detection of positive samples prior to sequencing (Fig. 5B, Tab. S2). Following sequencing, expected bacteria represented 89.4% of total DNA yield on average for 7 samples that reached 10⁴ CFU/mL under 8-hours versus 50.06% for the remaining 3 samples having relatively slow-growing species. All samples combined, 75.4% of the total DNA yield matched with the bacterial species initially used for spiking and enrichment and 17.64% with host species (Fig. 5C). Similar to BACT/ALERT positive samples, >20% abundance threshold successfully identified 10/10 bacterial species sequenced to validate the rapid enrichment protocol (Fig. 5C). Also, like before, as low as 10 Mbp yield (subsampled) was sufficient to accurately identify bacterial species with the abovementioned cutoff (Fig. S1 B).




Fig. 5: Rapid culture enrichment: species covered, overall accuracy in species and antimicrobial resistance prediction. (A) Time to reach 10⁴ colony forming units (CFU)/mL (green line; optimal concentration for chemical host DNA depletion (CHDD) with culture-based bacterial enrichment prior to M-15 CHDD and mNGS, tested with the top 15 bacterial species causing bloodstream infection. (B) DNA concentration (ng/μL) of the three strerile culture-enriched blood (SBC01-SBC03) and ten rapid (8-hours) culture enriched spiked blood samples, following M-15 CHDD, and whole genome amplification with the REPLI-g kit. Quantification was performed with Qubit broad range assay. (C) Proportion of expected bacteria (yellow; spiked initially) versus all other reads following M-15 CHDD and MinION sequencing. Species, genus and non-agreements from rapid culture-enriched samples are highlighted with the same colored labels as before. (D) Number and proportion of ResFinder true positive, true negative, false positive and false negative AMR predictions with M-15 mNGS compared to the whole genome sequencing (WGS) results of the same isolates/strains. MR: methicillin-resistant

In silico prediction of AMR is promising but requires improvement for clinical use

433 434

435

436

437

438 439

440

441

442

443

444

445

446

447

448

449

450

451

The accuracy of AMR prediction for the BACT/ALERT positive samples was determined comparing the ResFinder phenotype antibiotic data with the phenotypic culture-based antimicrobial susceptibility testing (AST) results (n= 257). For all 30 culture positive samples, mNGS exhibited 90.32% (232/257) categorical agreement overall, with 8.49% (18/212) major error and 15.55% (7/45) very major error (Fig. 4D). Among the 17 bacterial species,

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

discrepancies in resistance calls for K. michiganensis (5/18), K. pneumoniae (6/18), and S. aureus (5/18) contributed to the highest number of major errors, and E. coli (2/07) and S. epidermidis (2/07) towards very major error (Fig. 4E). Of 27 antibiotics for which results were compared, very major error for ciprofloxacin was most common (3/7), possibly due to the relatively low accuracy of ONT reads and the frequent association of resistance to fluoroquinolones with mutations in quinolone resistance determining region (QRDR) of DNA gyrase and topoisomerase encoding genes, as opposed to resistance encoding gene presence/absence in other antibiotics.[25] Clindamycin (4/18) and piperacillin/tazobactam (3/18) were the top two antibiotics exhibiting major errors (**Fig. 4F**). Due to the smaller number of ATCC strains and clinical isolates (n =10) tested, and unavailability of phenotypic AST data for a few clinical isolates, AMR predictions of M-15 mNGS with the rapid culture method were compared to whole genome sequencing (WGS) of pure bacterial strains predicted AMR of the same strains/species using ResFinder (n = 920 predictions). Overall categorical agreement for M-15 mNGS versus WGS was 98.7% (908/920) and mNGS exhibited 89.1% true susceptible, 9.6% true resistant, 1.3% false susceptible and no false resistant predictions (Fig. 5D). P. aeruginosa was the only species for which sequencing results did not match perfectly with its reference genome (12/92 predictions) and therefore was the only source of false susceptibility, possibly due to its high GC content leading to inefficient/uneven DNA amplification with the REPLI-g kit (Tab. S2). For both BACT/ALERT positive blood culture and rapid enriched spiked blood M-15 CHDD blood, ≥50 Mbp sequencing yield was sufficient to predict AST profiles, with the accuracy almost the same as having a sequencing yield of >100 Mbp per sample (Fig. S2, S3). Discussion Timely identification of pathogens and their antimicrobial resistance profile is crucial in BSI because more targeted and effective antibiotic therapy can minimise the progression and severity of the disease and therefore lead to improved patient outcomes. In addition, reduced prescription of broad-spectrum antibiotics may help preserve their effectiveness, limit the emergence of new antibiotic-resistant strains and protect the valuable microbiota that plays an important role in maintaining overall nutrition and health [26]. Rapid sequencing-based methods, especially in combination with selective chemical depletion

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

approaches, have the potential to reduce turnaround time and therefore lessen detrimental outcomes. In working towards this goal, this study initially assessed the effectiveness of five published and commercial, one in-house and one computation-based host depletion strategies. As a first step, we compared the effectiveness of an in-house host depletion method (M-15) with five published and commercial approaches, as well as a computation-based host depletion strategy. The host depletion efficiency of most of the CHDD workflows was outstanding (particularly for M-15 and P1). However, we also noticed a correlation between depletion efficiency and loss of bacterial DNA with some protocols (e.g., C2) showing significant negative bias towards some species. For samples with low bacterial abundance, the proportion of bacterial DNA was insignificant, ≤1% of total DNA, even after M-15 CHDD, which can remove >99.99% host DNA. However, bacteria represented >50% of total DNA sequence yield for the CHDD samples containing ≥10⁴ CFU/mL bacteria. This meant additional enrichment/depletion was necessary to get improved proportions of the sequencing yield that is bacterial. As a simple and cost-effective alternative, we realised that a culture-based enrichment step prior to CHDD and sequencing might improve DNA extraction efficiency/robustness and proportion of bacteria in the sample simultaneously. Therefore, we initially tested BACT/ALERT positive samples with two versions of M-15 mNGS protocols. As confirmed during the initial phase, the proportion of host: bacterial DNA sequenced was improved significantly with CHDD and AS. However, the sequencing yield was suboptimal when CHDD whole genome amplification (WGA) was paired directly with the Rapid Barcoding Kit (not systematically tested). The best output was observed when debranched MDA products were barcoded using the Ligation Sequencing Kit, although it requires additional hands-on time and potentially pricier reagents for library preparation. Both versions of the workflows have their own strengths and limitations; for example, the rapid workflow requires less hands-on time but may result in relatively low sequencing yield, leading to higher sequencing cost per sample (Fig. 1). In contrast, the high-yield workflow would reduce sequencing cost by providing greater output with only 90 additional minutes for sample processing (Fig. 1). Several studies have already highlighted this difference; [27, 28]

consequently, users may choose the workflow that best suits their need/budget.

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

Although there are multiple bioinformatic pipelines available for mNGS-based species identification, only a few have been developed/standardised for diagnosing bloodstream infection. The aim of this study was therefore not to benchmark these pipelines; instead, we assessed the utility of one of the well-regarded workflows, CZ ID, in combination with M-15 mNGS. With the 20% (200,000 BPM) abundance cutoff, sequencing accurately identified 3/3 negative, 28/28 mono-bacterial and 2/4 multi-bacterial species reported in two samples, with >88% DNA classified as the expected species. To determine minimum sequencing yield required to accurately identify bacterial species, we randomly subsampled the reads under the established assumption (Fig. 2C) that the proportion of host: bacteria remains consistent throughout a sequencing run [29]. The results demonstrated that the species prediction accuracy with the given cutoff remains nearly identical even with 10 Mbp yield per sample. Therefore, it is not entirely necessary to generate hundreds of Mbp reads/sample to cover ~100% of the genome with >20x depth for patient management unless the aim is to utilise this data for hospital outbreak investigation. With the rapid culture enrichment, only a few species tested reached/crossed ≥10⁴ CFU/mL threshold under 6 hours, and at least 8 hours of incubation was required to get more comprehensive representation of critically important Gram-positive (n=7) and Gram-negative (n=8) bacterial pathogens. M-15 CHDD and sequencing of a subset of rapid (8-hour) enriched samples (5 Gram-positive and 5 Gram-negative) further confirmed our hypothesis: sequence reads from expected bacteria represented >75% of total yield, and similar to BACT/ALERT positive samples, only 10 Mbp reads accurately identified species with the previously assigned abundance threshold. Regarding AMR prediction, it is worth highlighting that not all expected molecular mechanisms of antibiotic resistance have been determined [30]. Additionally, a mere presence or absence of genes and/or mutations does not always correlate to phenotypic resistance or susceptibility [30]. Therefore, at present, it is less likely that a sequencing-based approach would match culture-based phenotypic results with 100% accuracy for all the bacterial species commonly identified in BSI. Like species identification, several workflows can predict AMR using mNGS data. The underlying principles, databases and/or accuracy can vary among these workflows for AMR identification [31]. Therefore, it was decided to test ResFinder, a well-regarded workflow, with M-15 mNGS, as benchmarking several

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

workflows/bioinformatic pipelines was not within the scope of this study. M-15 mNGS combined with ResFinder exhibited overall 90.3% accuracy 8.49% major and 15.55% very major error with BACT/ALERT positive samples. These proportions closely match with some of the other studies that utilised culture enriched samples for metagenomic sequencing, although very major error rates with M-15 mNGS were found to be marginally lower [20]. With rapid culture-enriched samples, WGS data was used as comparator. Although this is less ideal than comparing with culture-based phenotypic results, we wanted to understand how closely mNGS results matched those of reference sequences of bacteria that were used for spiking. With 920 ResFinder AST predictions, mNGS showed 98.7% categorical agreement, and only 1.3% false susceptibility, primarily due to P. aeruginosa, the only species exhibiting discordant results. Similar suboptimal results with P. aeruginosa were also observed in the aforementioned study [20]. However, in our case, this likely stemmed from inefficient/uneven DNA amplification due to high GC content of P. aeruginosa (66.6%), as we did not observe any lysis/viability issues with culture when CHDD samples were plated on agars (Tab. S2). Considering the overall performance, it seems more work is required in terms of wet/dry lab to make AMR predictions more accurate (e.g., Q30 reads and/or utilizing machine learning models [32]) to be accepted as a replacement of blood culture and phenotypic assays. However, as an addition to existing methods, M-15 mNGS at its current stage still holds promise to inform treatment in comparison to empirical antibiotic therapy. For clinical management of BSI or infection in general, the accuracy of empirical treatment can range from 20% to 80% [33-35]. This means that a high proportion of cases receive inappropriate antibiotics until more targeted therapy is administered utilizing the phenotypic AST results (conventionally available in 48-72 hours), potentially risking detrimental outcomes for critically ill patients [34]. With the rapid availability of bacterial species and AMR predictions that surpass empiric prescription and therapy, mNGS can significantly refine the choice of antimicrobials, increasing the likelihood of favourable outcomes. That being said, thorough clinical validation would be required for rapid M-15 mNGS to be recommended for clinical implementation. A possible costly drawback when implementing the rapid enrichment approach was the necessity to blindly sequence all blood cultures if the culture positive and negative samples could not be differentiated prior to sequencing. However, when compared to the negative

blood samples, both BACT/ALERT positive and rapid enriched spiked M-15 CHDD blood had 152x and 28x higher dsDNA concentration following MDA, meaning any negative samples could potentially be filtered out prior to sequencing if their Qubit-measured DNA concentration provides a differentiable signature, as we observed following CHDD and WGA (Tab. S1, S2). However, the exact cutoff must be determined site-wise (different clinical settings or in different laboratories) with more negative patient samples before implementation in a clinical setting. It is important to note that this differentiation is only possible with rapid CHDD as direct extraction and amplification would not provide a discernible characteristic for negative samples due to the overwhelming abundance of host DNA masking the unique signature from the bacteria (Tab. S2). This approach may incorrectly flag some slow growing and/or bacterial species with high GC% as negative. However, because M-15 mNGS is currently intended to complement existing technologies rather than replacing them, species that might be missed would still be captured with traditional culturebased methods. It is important to recognise that this study had several limitations. Since we only had access to different volumes of surplus EDTA treated blood samples from the suspected BSI cases, stored in a refrigerator for up to five days until reporting was complete, it was decided not to test the rapid enrichment workflow on patient samples. Instead, 15 clinically important bacterial species were chosen for initial validation. This is because the different volume and extended storage of the samples might alter the host/pathogen ratio, affect viability, and/or change the actual growth of the bacteria and therefore might not be an appropriate representative of freshly drawn samples. Also, the rapid and high yield mNGS workflows were benchmarked, and a few batches of samples were initially processed using R9.4.1 flow cells, before more accurate R10.4.1 kits became widely available on the market. Therefore, it was decided to continue testing all the samples with library kits compatible with R9.4.1 flow cells [27]. We believe that the performance of M-15 CHDD would be further enhanced with the use of newer versions of kits/flow cells, as a higher proportion of ≥Q20 reads would likely allow mutations associated with AMR to be more reliably predicted.

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

Conclusions

In summary, in this study, we demonstrated that M-15 CHDD paired with a rapid barcoding or ligation sequencing workflow is highly effective at species and AMR gene detection in BACT/ALERT positive and rapid culture enriched samples. This approach can deplete significant amount of host DNA and facilitate rapid bacterial/AMR identification, with a handson time of less than 4 (rapid barcoding kit) and 6 hours (ligation sequencing kit), plus time required to generate 10 Mbp (species)/≥50 Mbp (AMR) sequencing yield per sample. The time to achieve this yield can vary depending on the capacity of the flow cells used and/or the number of samples multiplexed in a sequencing run, therefore, it is up to the user to choose the appropriate flow cell and/or number of samples based on their needs. However, we demonstrated that with 8-hour culture enrichment, M-15 mNGS can predict causative bacterial species and accurately detect AMR determinants within 13-15 hours of sample collection, and thus has the potential to improve patient outcomes in BSI.

630	Abbreviations
631	AMR: Antimicrobial resistance
632	AS: Adaptive sampling
633	AST: Antimicrobial susceptibility testing
634	ATCC: American Type Culture Collection
635	BSI: Bloodstream infection
636	BPM: Bases per million
637	CFU: Colony-forming units
638	CHDD: Chemical host DNA depletion
639	dsDNA: Double-stranded DNA
640	EUCAST: European Committee on Antimicrobial Susceptibility Testing
641	FDA: Food and Drug Administration (USA)
642	GC%: Guanine-cytosine content percentage
643	mNGS: Metagenomic next-generation sequencing
644	Mbp: Megabase pairs
645	MDA: Multiple displacement amplification
646	NHS: National Health Service (UK)
647	ONT: Oxford Nanopore Technologies
648	PBS: Phosphate-buffered saline
649	qPCR: Quantitative polymerase chain reaction
650	RBC: Red blood cells
651	WGA: Whole-genome amplification
652	WGS: Whole-genome sequencing

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

Funding This study was funded by Royal Society Research Grant (RGS\R1\211163) and University of Glasgow's Lord Kelvin Adam Smith (LKAS) Ph.D. studentship. **Ethical statement** This study was reviewed and approved by the University of Glasgow College of Medical, Veterinary & Life Sciences Ethics Committee (Project No: 200210015) and UK National Health Services (NHS) Greater Glasgow and Clyde (R&I reference: GN19ID331). No personal information from the patients and healthy volunteers was collected and used in this study. Human DNA reads obtained from mNGS were excluded or not utilised for any bioinformatics analyses beyond quantifying the number of hosts reads generated. Availability of data and materials All the raw sequencing reads (fastq.gz: host excluded) analysed and presented in this study are available on European Nucleotide Archive under the study accession "PRJEB80726". Authors' contributions Conceptualisation of this study was carried out by TF and MSIS. Data generation, cleaning, management, formal analysis, and initial draft was written by MSIS. Project investigation, experimental method selection, clinical sample collection, formal review and coordination was done by TF, KB, KO, PE, MEM, CW, MF, and MSIS. TF (RS) and MSIS (LKAS) acquired funding for this project. Acknowledgements We would like to thank Kareen Macleod for generously providing the reference isolates used in this study. We also want to express our gratitude to Ryan Carter and Ângelo Mendes for their help and input on this project.

References

- 680 1. Ikuta KS, Lucien R. Swetschinski, Gisela R. Aguilar, Fablina Sharara, Tomislav Mestrovic, 681 Authia P. Gray, Nicole D. Weaver: Global mortality associated with 33 bacterial 682 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 683 **2019.** Lancet 2022, **400:**2221-2248.
- 2. 684 Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, Martin-685 Loeches I, Leone M, Lupu MN, Vincent JL, Investigators I: Sepsis in Intensive Care Unit 686 Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum 687 Infect Dis 2018, **5:**ofy313.
- Tabak YP, Vankeepuram L, Ye G, Jeffers K, Gupta V, Murray PR: Blood Culture 688 3. 689 Turnaround Time in U.S. Acute Care Hospitals and Implications for Laboratory 690 Process Optimization. J Clin Microbiol 2018, 56:10-1128.
- 691 4. Paharik AE, Schreiber HLt, Spaulding CN, Dodson KW, Hultgren SJ: Narrowing the 692 spectrum: the new frontier of precision antimicrobials. Genome Med 2017, 9:110.
- 693 Chiu CY, Miller SA: Clinical metagenomics. Nature Reviews Genetics 2019, 20:341-5. 694 355.
- Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, 695 6. 696 Turner DJ, Wain J, et al: Nanopore metagenomics enables rapid clinical diagnosis of 697 bacterial lower respiratory infection. Nat Biotechnol 2019, 37:783-792.
- 698 7. Trung NT, Hien TT, Huyen TT, Quyen DT, Van Son T, Hoan PQ, Phuong NT, Lien TT, Binh MT, 699 Van Tong H, et al: Enrichment of bacterial DNA for the diagnosis of blood stream 700 infections. BMC Infect Dis 2016, 16:235.
- 701 8. Marotz CA, Sanders JG, Zuniga C, Zaramela LS, Knight R, Zengler K: Improving saliva 702 shotgun metagenomics by chemical host DNA depletion. Microbiome 2018, 6:1-9.
- 703 9. Heravi FS, Zakrzewski M, Vickery K, Hu H: Host DNA depletion efficiency of 704 microbiome DNA enrichment methods in infected tissue samples. J Microbiol 705 Methods 2020, 170:105856.
- 706 10. McQuillan JS, Wilson MW: 'Ready Mixed', improved nucleic acid amplification assays 707 for the detection of Escherichia coli DNA and RNA. J Microbiol Methods 2019, 708 **165:**105721.
- 709 11. Lee CS, Wetzel K, Buckley T, Wozniak D, Lee J: Rapid and sensitive detection of 710 Pseudomonas aeruginosa in chlorinated water and aerosols targeting gyrB gene 711 using real-time PCR. J Appl Microbiol 2011, 111:893-903.
- 712 12. Wood C, Sahl J, Maltinsky S, Coyne B, Russakoff B, Yague DP, Bowers J, Pearson T: 713 SaQuant: a real-time PCR assay for quantitative assessment of Staphylococcus 714 aureus. BMC Microbiol 2021, 21:174.
- 715 13. Bohl JA, Lay S, Chea S, Ahyong V, Parker DM, Gallagher S, Fintzi J, Man S, Ponce A, Sreng 716 S, et al: Discovering disease-causing pathogens in resource-scarce Southeast Asia 717 using a global metagenomic pathogen monitoring system. Proc Natl Acad Sci USA 718 2022, **119:**e2115285119.
- 719 14. Miles AA, Misra SS, Irwin JO: The estimation of the bactericidal power of the blood. J 720 Hyg (Lond) 1938, **38:**732-749.
- 721 15. Nurk S, Koren S, Rhie A, Rautiainen M, Bzikadze AV, Mikheenko A, Vollger MR, Altemose 722 N, Uralsky L, Gershman A, et al: The complete sequence of a human genome. Science 723 2022, 376:44-53.
- 724 16. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe 725 RL, Rebelo AR, Florensa AF, et al: ResFinder 4.0 for predictions of phenotypes from 726 genotypes. J Antimicrob Chemother 2020, 75:3491-3500.
- 727 17. Li H: Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 2018, 728 **34:**3094-3100.

- 729 18. Hall M: Rasusa: Randomly subsample sequencing reads to a specified coverage. 730 Journal of Open Source Software 2022, 7:3941.
- 731 19. Giske CG, Turnidge J, Canton R, Kahlmeter G, Committee ES: Update from the 732 European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin 733 Microbiol 2022, 60:e0027621.
- 734 20. Harris PNA, Bauer MJ, Lueftinger L, Beisken S, Forde BM, Balch R, Cotta MO, 735 Schlapbach L, Raman S, Shekar K: Rapid nanopore sequencing and predictive 736 susceptibility testing of positive blood cultures from intensive care patients with 737 **sepsis.** *Microbiology spectrum* 2024, **12:**e03065-03023.
- 738 Huang TH, Tzeng YL, Dickson RM: FAST: Rapid determinations of antibiotic 21. 739 susceptibility phenotypes using label-free cytometry. Cytometry A 2018, 93:639-648.
- 740 22. Ospino MC, Engel K, Ruiz-Navas S, Binns WJ, Doxey AC, Neufeld JD: Evaluation of 741 multiple displacement amplification for metagenomic analysis of low biomass 742 samples. ISME Commun 2024, 4:ycae024.
- 743 23. Sobol MS, Kaster AK: Back to Basics: A Simplified Improvement to Multiple 744 Displacement Amplification for Microbial Single-Cell Genomics. Int J Mol Sci 2023, 745 **24:**4270.
- 746 24. Wang MC, Lin WH, Yan JJ, Fang HY, Kuo TH, Tseng CC, Wu JJ: Early identification of 747 microorganisms in blood culture prior to the detection of a positive signal in the 748 BACTEC FX system using matrix-assisted laser desorption/ionization-time of flight 749 mass spectrometry. J Microbiol Immunol Infect 2015, 48:419-424.
- 750 25. Neyestani Z, Khademi F, Teimourpour R, Amani M, Arzanlou M: Prevalence and 751 mechanisms of ciprofloxacin resistance in Escherichia coli isolated from 752 hospitalized patients, healthy carriers, and wastewaters in Iran. BMC Microbiol 753 2023, 23:191.
- 754 26. Valdes AM, Walter J, Segal E, Spector TD: Role of the gut microbiota in nutrition and 755 health. BMJ 2018, **361:**k2179.
- 756 27. Ni Y, Liu X, Simeneh ZM, Yang M, Li R: Benchmarking of Nanopore R10.4 and R9.4.1 757 flow cells in single-cell whole-genome amplification and whole-genome shotgun 758 sequencing. Comput Struct Biotechnol J 2023, 21:2352-2364.
- 759 28. ONT: Premium whole genome amplification-Oxford Nanopore Technologies. 760 Ligation sequencing gDNA. SQK-LSK109. 2022.
- 761 29. Taxt AM, Avershina E, Frye SA, Naseer U, Ahmad R: Rapid identification of pathogens, 762 antibiotic resistance genes and plasmids in blood cultures by nanopore 763 sequencing. Sci Rep 2020, 10:7622.
- 764 30. Su M, Satola SW, Read TD: Genome-Based Prediction of Bacterial Antibiotic 765 **Resistance.** *J Clin Microbiol* 2019, **57:**10.1128/jcm. 01405-01418.
- 766 Doyle RM, O'Sullivan DM, Aller SD, Bruchmann S, Clark T, Coello Pelegrin A, Cormican 31. 767 M, Diez Benavente E, Ellington MJ, McGrath E, et al: Discordant bioinformatic 768 predictions of antimicrobial resistance from whole-genome sequencing data of 769 bacterial isolates: an inter-laboratory study. Microb Genom 2020, 6:e000335.
- 770 32. Ali T, Ahmed S, Aslam M: Artificial Intelligence for Antimicrobial Resistance 771 Prediction: Challenges and Opportunities towards Practical Implementation. 772 Antibiotics (Basel) 2023, **12:**523.
- 773 33. Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N: Incidence and outcome of 774 inappropriate in-hospital empiric antibiotics for severe infection: a systematic 775 review and meta-analysis. Crit Care 2015, 19:1-12.
- 776 34. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP, 777 Palmore TN, Rhee C, et al: Inappropriate empirical antibiotic therapy for 778 bloodstream infections based on discordant in-vitro susceptibilities: a

retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis 2021, 21:241-251. 35. Luo Y, Guo Z, Li Y, Ouyang H, Huang S, Chen Y, Li K, Ji Y, Zhu H, Luo W, et al: Appropriateness of Empirical Antibiotic Therapy in Hospitalized Patients with Bacterial Infection: A Retrospective Cohort Study. Infect Drug Resist 2023, 16:4555-4568.

Supplementary Figures, tables and protocols

801

802 803

804 805

806 807




Fig. S1: Accuracy of species prediction with varying sequencing yield (100 Mbp to 10 Mbp), identified by subsampling the (A) reads from 17 bacterial species from the 30 BACT/ALERT positive blood culture samples and (B) 10 rapid (8-hours) culture enriched spiked blood samples. Analysis was performed similarly using CZ ID with the same abundance threshold for all the species tested. Colored gradient highlights the species that passed the initial threshold filter and their abundance (base per million) in the CHDD samples that were sequenced.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.




Fig. S2: Antibiotic susceptibility profiles predicted with varying sequencing yield (>100 Mbp to 10 Mbp/sample) using subsampled reads from the 30 BACT/ALERT positive blood culture samples. (A) The heatmap is showing antimicrobial resistance profiles and (B) the barplot highlights the number of antimicrobials from different antibiotic classes identified with different sequencing yield for BACT/ALERT positive samples.




Fig. S3: Antibiotic susceptibility profiles predicted with varying sequencing yield (>50 Mbp to 10 Mbp/sample) using the subsampled reads from 10 rapid culture enriched (8-hours) spiked blood samples. (A) The heatmap shows antimicrobial resistance profiles and (B) the barplot highlights the number of antimicrobials from different antibiotic classes identified with different sequencing yield for rapid culture enriched spiked blood samples.

Tab. S1: Double stranded DNA concentration of three BACT/ALERT negative (BCN01 to BCN03) and 30 BACT/ALERT positive blood culture (BCP) samples quntified by Qubit following M-15 CHDD and 60 minutes of multiple displacement amplification with REPLI-g kit. As controls, six samples (BCN01 to BCN03 and BCP01 to BCP03) were also extracted directly and amplified similarly for 60 minutes without CHDD. Viability of bacterial following M-15 CHDD was confirmed by plating the supernatant on nutrient and blood agar media.

Sample	Accession	Organism	Culture	GC content (%)	Viability after M-15 CHDD	CHDD samples DNA (ng/μL)	No-CHDD samples DNA (ng/μL)
BCN01	ERR13759391	Not detected	Negative	N/A	N/A	1.6	733
BCN02	ERR13759392	Not detected	Negative	N/A	N/A	2.8	767
BCN03	ERR13759393	Not detected	Negative	N/A	N/A	5.5	760
BCP01	ERR13759394	S. pyogenes	Positive	38.5	Viable	209	490
BCP02	ERR13759395	S. aureus	Positive	32.8	Viable	201	920
ВСР03	ERR13759396	E. coli	Positive	50.8	Viable	350	940
BCP04	ERR13759397	S. pyogenes	Positive	38.5	Viable	291	Not tested
BCP05	ERR13759398	S. epidermidis	Positive	33.0	Viable	950	Not tested
ВСР06	ERR13759399	S. epidermidis	Positive	33.0	Viable	620	Not tested
BCP07	ERR13759400	B. luteolum	Positive	67.8	Viable	17.4	Not tested
BCP08	ERR13759401	M. luteus	Positive	74.0	Not viable	9.44	Not tested
ВСР09	ERR13759402	P. mirabilis	Positive	38.8	Viable	235	Not tested
BCP10	ERR13759403	S. agalactiae	Positive	35.5	Viable	77.8	Not tested
BCP11	ERR13759404	E. coli	Positive	50.8	Viable	1480	Not tested
BCP12	ERR13759405	E. coli	Positive	50.8	Viable	342	Not tested
BCP13	ERR13759406	K. michiganensis	Positive	55.5	Viable	1390	Not tested
BCP14	ERR13759407	E. coli	Positive	50.8	Viable	843	Not tested
BCP15	ERR13759408	K. variicola	Positive	57.3	Viable	1340	Not tested
BCP16	ERR13759409	S. agalactiae	Positive	35.5	Viable	325	Not tested
BCP17	ERR13759410	L. adecarboxylata	Positive	52.55	Viable	111	Not tested
BCP18	ERR13759411	E. coli	Positive	50.8	Viable	1170	Not tested
BCP19	ERR13759412	S. aureus	Positive	32.8	Viable	326	Not tested
BCP20	ERR13759413	S. maltophilia	Positive	66.7	Viable	18.1	Not tested
BCP21	ERR13759414	S. epidermidis	Positive	33.0	Viable	440	Not tested
BCP22	ERR13759415	E. faecalis	Positive	37.5	Viable	432	Not tested
BCP23	ERR13759416	K. pneumoniae	Positive	57.3	Viable	680	Not tested
BCP24	ERR13759417	P. mirabilis	Positive	38.7	Viable	860	Not tested
BCP25	ERR13759418	E. coli	Positive	50.8	Viable	1033	Not tested
BCP26	ERR13759419	S. gallolyticus	Positive	37.69	Viable	297	Not tested
BCP27	ERR13759420	S. aureus	Positive	32.8	Viable	228	Not tested
BCP28	ERR13759421	A. xylosoxidans	Positive	64.0	Viable	84	Not tested
BCP29	ERR13759422	S. epidermidis	Positive	33.0	Viable	406	Not tested
ВСР30	ERR13759423	C. jejuni	Positive	30.3	Viable	348	Not tested

833

834

835

836 837

Tab. S2: Double stranded DNA concentration of three 8-hour culture enriched sterile blood (HB1 to HB3) versus ten spiked blood (1-10 CFU) samples following 60 minutes of multiple displacement amplification with REPLI-g kit with and without M-15 chemical host DNA depletion (CHDD) measured by Qubit. Viability of bacteria following M-15 CHDD was confirmed by plating the supernatant on nutrient and blood agars.

Sample	Organism	Culture	GC content (%)	Viability after M- 15 CHDD	CHDD samples DNA (ng/μL)	No-CHDD samples DNA (ng/μL)
HB1	Not detected	Negative	NA	N/A	4.2	652
HB2	Not detected	Negative	NA	N/A	8.1	487
HB3	Not detected	Negative	NA	N/A	4.18	513
RESB1	S. aureus	Positive	32.8	Viable	131	510
RESB2	E. faecium	Positive	37.8	Viable	122	611
RESB3	S. pyogenes	Positive	38.5	Viable	140	377
RESB4	S. agalactiae	Positive	35.6	Viable	177	647
RESB5	S. pneumoniae	Positive	39.7	Not viable	83	550
RESB6	P. aeruginosa	Positive	66.6	Viable	43	449
RESB7	K. quasipneumoniae	Positive	57.2	Viable	213	714
RESB8	A. baumannii	Positive	39	Viable	156	699
RESB9	E. coli	Positive	50.8	Viable	248	892
RESB10	P. mirabilis	Positive	38.88	Viable	233	621

Tab. S3: AMR gene profile (genes expected based on whole genome sequencing data) of the 8-hour culture-enriched blood samples chosen for sequencing (n=10). Following M-15 mNGS, sequencing reads were analysed with ResFinder to match and confirm the presence/absence of the same AMR determinants expected from the species initially utilised for spiking. Prediction accuracy of AMR (Match%) was determined comparing the ResFinder predicted phenotypic AST results of M-15 mNGS versus previously sequenced clinical/ATCC strains.

Sampl e	Accession	Organism	Source	Genes expected	Genes found (M- 15)	Gene Match	Phenotyp e Match (%)
RESBO 1	ERR13759428	S. aureus	NCTC 12493	mecA, ant(9)-la, erm(A), tet(K)	mecA, ant(9)-la, erm(A), tet(K)	4/4	100
RESB0 2	ERR13759429	E. faecium	Clinical isolate	aac(6')-II, ant(6)-Ia, aph(3')-III, aph(2'')-Id, erm(B), msr(C), Isa(E), tet(M)	aac(6')-II, ant(6)-Ia, aph(3')-III, aph(2'')- Id, erm(B), msr(C), Isa(E), tet(M)	8/8	100
RESBO 3	ERR13759430	S. pyogenes	Clinical isolate	-	-	0/0	100
RESBO 4	ERR13759431	S. agalactiae	Clinical isolate	mre(A)	mre(A)	1/1	100
RESB0 5	ERR13759432	S. pneumoniae	ATCC 6303	-	-	0/0	100
RESBO 6	ERR13759433	P. aeruginosa	ATCC 27853	aph(3')-IIb, blaPAO, blaOXA-396, fosA, catB7, crpP	catB7, crpP	6/2	86.9
RESBO 7	ERR13759434	K. quasipneum oniae	ATCC 700603	ant(2")-la, blaOKP-B, blaSHV-18, blaOXA-2, fosA, OqxA, OqxB, sul1	ant(2'')-Ia, blaOKP- B, blaSHV-18, blaOXA-2, fosA, OqxA, OqxB, sul1	8/8	100
RESB0 8	ERR13759435	A. baumannii	Clinical isolate	blaOXA-343, blaADC-25	blaOXA-343, blaADC-25	2/2	100
RESBO 9	ERR13759436	E. coli	Clinical isolate	aph(3'')-lb, aph(6)-ld, blaTEM-1C, sul2	aph(3")-Ib, aph(6)- Id, blaTEM-1C, sul2	4/4	100
RESB1 0	ERR13759437	P. mirabilis	Clinical isolate	tet(J)	tet(J)	1/1	100

Tab. S4: Primer, probe sequences and their reaction concentrations used in this study for detecting universal 16S (bacteria) and 18S Ribosomal ribonucleic acid-rRNA (host) genes and species-specific genes to identify three bacterial species, (Escherichia coli (EC), Pseudomonas aeruginosa (PA), and Staphylococcus aureus (SA)) used for initial spiking and benchmarking experiments.

Genes	Primer/Probe name	Primer/Probe Conc (nM)	Sequence (5'-3')	Reference	
	16S rRNA_341_F	400	CCTACGGGAGGCAGCAG		
16S rRNA	16S rRNA_534_R	400 -	ATTACCGCGGCTGCTGG	— Heravi et al [9].	
	16S rRNA_P	100	FAM-CCGCGTGWRTGAWGAAGGYCTTCG-BHQ1	This study	
	18S rRNA_756_F	400 -	GGTGGTGCCCTTCCGTCA	Lloravi et al [0]	
18S rRNA	18S rRNA_877_R	400	CGATGCGGCGGCGTTATT	Heravi et al [9].	
	18S rRNA_P	100	Hex- ACCCAAAGACTTTGGTTTCCCGGA- BHQ1	This study	
EC_ybbW	EC_ybbW_F	· 80 -	TGATTGGCAAAATCTGGCCG		
	EC_ybbW_R	80 =	GAAATCGCCCAAATCGCCAT	─ McQuillan et al [10].	
	EC_ybbW_P	40	FAM-CCGCCGAAAACGATATAGATGCACGG-BHQ1		
	PA_GB722_F	F00	GGCGTGGGTGTGGAAGTC		
PA_GB722	PA_GB722_R	· 500 -	TGGTGAAGCAGAGCAGGTTCT	Lee et al [11].	
	PA_GB722_P	250	FAM-TGCAGTGGAACGACA-BHQ1	_	
SA_SaQuant	SA_SaQuant_F	1000 -	AACTACTAGGGGAGCCTAATRAT		
	SA_SaQuant_R	1000 =	GGTACTAACCAAATCAGGTCATAA	Wood et al [12].	
	SA_SaQuant_P	200	FAM-TGGCTGAGATGAAYTGTTCAGACCC-BHQ1	_	

Supplement Protocol: M-15 mNGS

Consumables

900

Name	Concentration/units	Commercial source	Comments
Saponin	Final concentration 2.25%	Tokyo chemical industry, Cat: S0019	To make a 4.5% or 2.25% w/v solution, dissolve 4.5/2.25 grams of Saponin into 50 ml sterile nuclease free H ₂ O. Mix thoroughly until dissolved. Adjust the volume to 100ml. Sterilize using 0.2 μm filter, and store at 4 °C for up to 3 weeks
NaCl	5M	Promega, Cat: V4221	NA
DNase I	300 units/μL	Invitrogen, Cat: 18047019	NA
DNase I buffer	10x solution	NEB, Cat: B0303SVIAL	10x buffer = 10 mM Tris HCl, 2.5 mM MgCl2, 0.5 mM CaCl2
Trypsin-EDTA	0.05%, phenol red	ThermoFisher Cat: 25300054	NA
Molecular grade H20	NA	Qiagen, Cat: 129114	NA
DPBS	1x solution	ThermoFisher Cat: 14190144	Without calcium, magnesium, or phenol
T7 Endonuclease I	NA	NEB, Cat: M0302S or M0302L	NA
DNA binding beads	NA	Aline biosciences, Cat: C-1003-50	NA
Molecular grade ethanol	NA	Sigmaaldrich, Cat: 51976-500ML-F	NA

Name	Concentration/units	Commercial source	Comments
REPLI-g Single Cell Kit	NA	Qiagen, Cat: 150343 or 150345	NA
Qubit dsDNA Be assay Kit	NA	ThermoFisher, Cat: Q32853	NA
Qubit assay tubes	NA	ThermoFisher, Cat: Q32856	NA
Rapid Barcoding Kit	NA	ONT, Cat: SQK- RBK004	Required for the rapid sequencing protocol
Long Fragment Buffer Expansion	NA	ONT, Cat: EXP- LFB001	Required for the rapid sequencing protocol
Ligation Sequencing Kit	NA	ONT, Cat: SQK- LSK109	Required for the high yield protocol
Native Barcoding Expansion Kit	NA	ONT, Cat: EXP- NBD196	Required for the high yield protocol
NEBNext Ultra II End Repair/dA- Tailing Module	NA	NEB, Cat: E7546L	Required for the high yield protocol
Blunt/TA Ligase Master Mix	NA	NEB, Cat: M0367L	Required for the high yield protocol
NEBNext Quick Ligation Module	NA	NEB, Cat: E6056L	Required for the high yield protocol
Flow Cell Priming Kit	NA	ONT, Cat: EXP- FLP002	Required for both protocols
Flow Cell Wash Kit	NA	ONT, Cat: EXP- WSH004	Required for both protocols
ONT Flow Cell R9.4.1	NA	ONT, Cat: FLO- MIN106 or FLO- FLG001	Required for both protocols
Magnetic rack/plate holder	NA	ThermoFisher, Cat: 12331D and 12321D	NA

Name	Concentration/units	Commercial source	Comments
PCR Tube Strip with Attached Flat Caps	NA	ThermoFisher, Cat: AB2000	NA
1.5 ml DNA LoBind tubes	NA	Eppendorf, Cat: 0030108051-250EA	Use LoBind tubes
2 ml round bottom tubes	NA	Starlab, Cat: S1620- 2700-C or Eppendorf, Cat: 0030120094	Avoid using LoBind tubes
Pipettes and pipette tips P2, P10, P20, P100, P200, Multichannel	NA	Any	NA
Centrifuge /Microplate centrifuge	NA	Any	NA
Vortex mixer	NA	Any	NA
Thermal cycler	NA	Any	NA
Heating block for 1.5/2 mL tubes	NA	Any	NA
Sequencing device	NA	Flongle, MinION Mk1B, GridION	NA
Device for live basecalling	NA	GridION or A powerful laptop	A laptop with minimum 8 Gb GPU (RTX 3060 or higher), 16 GB Ram, 1 Tb M.2 NVMe SSD

Disclaimer: Some parts of the following protocol has been copied directly from the manufacturer's official website or from the kit manual. Therefore, all the proprietary information mentioned below remains the sole property of the kits manufacturer.

902

903

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

Before sample preparation It is important to divide all reagents into smaller aliquots to avoid multiple freeze-thaw cycles and reduce the likelihood of cross-contamination. Warm up 0.05% trypsin EDTA at 37°C. Prepare 1x DNase I buffer and store in the fridge before use. Make a fresh batch of REPLI-g Master Mix following manufacturer's instructions. Take out aliquots of Buffer D2, Stop Solution, and any other reagents from the freezer, and store in the refrigerator or on ice until needed. Thaw all the reagents at room temperature or on ice as per manufacturers recommendation. This protocol can be used on BD BACTEC (Becton, Dickinson and Company, NJ, USA) or any blood culture (FPBC) samples flagged positive with an automated culture system. Protocol M-15 mNGS can also be applied to rapid culture enriched blood samples (REBC; for example, 1-10 mL patient blood samples incubated for 8 hours in BD BACTEC media bottles), once the enriched sampled have at least 10³ CFU/mL bacterial concentration. FPBC samples can be used directly for CHDD; however, REBC samples need to be pre-processed to concentrate the sample before continuing with this protocol. It is crucial to use fresh samples for CHDD, as frozen or improperly stored samples can lead to the lysis of bacterial cells. This may lead to a considerable loss of bacterial DNA during CHDD. Pre-processing REBC samples Transfer 1.5 mL REBC samples aseptically to a 2 mL round bottom microcentrifuge tube and spin at 8,000xg for 5 minutes. Slowly aspirate the supernatant without disturbing the pellet and gently resuspend the pellet in 800 µL 2.25% saponin. Proceed to the step 2 of CHDD protocol below. Note* It is important to use round/wide bottom 2 mL microcentrifuge tubes to minimize bacterial cell loss while aspirating the supernatant during the initial washing steps.

1. Add 400 μ L FPBC sample to 400 μ L 4.5% saponin (final saponin concentration will be 2.25%

- after mixing) in a 2 mL wide bottom sterile microcentrifuge tube and gently pipette mix for at
- 936 least 4 to 5 times.

Host depletion

933

934

- 2. Add 1 μL DNase I (300 units/μL) to the REBC/FPBC sample, pulse vortex at low speed for 5 937
- 938 seconds and incubate the sample at 25°C in a heating block for 10 minutes at 800 rpm.
- 939 Note* Adding DNase I decreases the viscosity of the sample by degrading a substantial amount of DNA
- 940 (desirably from the host) after selective host cell lysis. The DNA released from the host cells can be extremely
- 941 sticky, and often adhere to pipette tips or microfuge tubes. As a result, there's a risk of losing desired/targeted
- 942 bacterial cells because they might adhere to the sticky host DNA and get affixed to the pipette tips and/or
- 943 microcentrifuge tube.
- 3. Perform a quick spin and add 800 µL molecular grade water to the sample. Pipette mix 4 to 944
- 5 times and incubate for 1 minute at room temperature. 945
- 4. Add 44 µL 5 M molecular grade NaCl (final concentration is 137 mM; same as PBS) to the 946
- sample, invert the tubes 3 to 4 times to mix and centrifuge at 10,000x g for 5 minutes. 947
- 5. Carefully remove the supernatant without touching or disturbing the pellet and resuspend 948
- 949 in 1 mL molecular grade 1x Dulbecco's Phosphate Buffered Saline (DPBS, Without calcium,
- 950 magnesium, or phenol).
- 951 6. Centrifuge the sample at 10,000x g for 3 minutes and carefully remove the supernatant
- without touching or disturbing the pellet. 952
- 7. Resuspend the pellet in 398 μL 1x DNase I buffer, add 2 μL DNase I (300 units/μL) to the 953
- 954 sample and incubate at 37°C with shaking at 800 RPM for 15 minutes.
- 8. Following incubation, add 1 mL 0.05% trypsin EDTA directly to the sample, pipette mix at 955
- 956 least 8 to 10 times and incubate at room temperature for 1 minute.
- 957 Note* Some bacterial cells may form aggregates in the sample, so adding 0.05% trypsin EDTA can separate the
- 958 cells and ensure an even distribution for subsequent procedures. The trypsinisation step does not affect
- 959 bacterial viability and/or cell wall integrity.
- 960 9. Repeat step 6 and resuspend the pellet in 1 mL 1x DPBS.

961 Note* This is the end of host depletion with M-15. After this, 4 µL of host depleted bacterial cell material in 962 DPBS from step 9 can be used directly for alkaline lysis and whole genome amplification (WGA; protocol 1) using 963 the REPLI-g Single Cell Kit.

DNA extraction and Whole Genome Amplification

965 10. Prepare sufficient Buffer D2 in a PCR tube for the total number of 12 reactions.

Reagent	Volume (μL)
DTT, 1M	3
Buffer DLB	33
Total	36

964

967

966 Note* Buffer D2 should not be stored longer than 2 months at-20 °C.

- 11. Place 4 μL cell material into a PCR tube containing 3 μL buffer D2. Mix by flicking the tube 968 and centrifuge briefly.
- 12. Incubate at 65°C for 10 min with heated lid on and then add 3 µL Stop Solution. Mix by 969 flicking the tube and centrifuge briefly. Prepare a master mix according to the instruction 970 971 below.

Reagent	Volume (μL)
REPLI-g sc Reaction Buffer	14
REPLI-g sc DNA Polymerase	1
Total	15

- 972 Note* Avoid using H₂O for preparing the master mix.
- 13. For each reaction, add 5 µL DNA from step 12 and incubate at 30°C for 1 hour with 973 heated lid off. 974
- 14. Inactivate REPLI-g sc DNA Polymerase by heating the sample for 3 min at 65°C with 975 976 heated lid on.
- 977 Note* After this step amplified host depleted DNA can be diluted 5-fold in molecular grade H₂O, measured with 978 Qubit Br assay and used directly for debranching and subsequently sequencing library preparation.

Debranching and bead cleanup

980 15. In a clean 0.2 mL PCR tube, mix the reagents for debranching in the following order.

It is made available under a CC-BY-	NC-ND 4.0 International license
-------------------------------------	---------------------------------

Reagent	Volume (μL)
600 ng of amplified DNA	To make 30 μL
NEBuffer 2	3
T7 Endonuclease I	1.5
Nuclease free H₂O	25.5- To make 30 μL
Total	30

- 982 16. Mix the reagents by flicking the tube and centrifuge briefly. Incubate the reaction for 10983 minutes at 37°C.
- 984 17. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.
- 985 18. Add 15 μL of the bead suspension (0.5x) to the DNA sample and mix by pipetting.
- 986 19. Incubate for 5 minutes at room temperature.
- 987 20. Spin down and pellet the sample on a magnetic rack/plate until supernatant is clear and988 colourless. Keep the tube on the magnet, and pipette off the supernatant.
- 21. Keeping the tube on the magnet, wash the beads with 200 μL of freshly prepared 70%
 ethanol without touching/disturbing the pellet. Remove the ethanol carefully using a
 pipette and discard.
- 992 22. Repeat the previous ethanol washing step.
- 23. Spin down and put the tube back on the magnetic rack/plate. Pipette off any residual
 ethanol. Open the lid and allow the tubes to dry for ~30 seconds, but do not dry the
 pellet to the point of cracking.
- 996 24. Remove the tube from the magnetic rack/plate and resuspend the pellet in 15 μ L 997 nuclease-free water. Incubate for 2 min at room temperature.
- 998 25. Pellet the beads on a magnet until the eluate is clear and colourless.
- 999 26. Remove and retain 12 μL of eluate into a clean 0.2 mL PCR tube.
- Note* This is the end of debranching and DNA cleanup. After this step, cleaned and debranched DNA products
 can be used for library preparation with Rapid Barcoding (rapid but low yield) or Ligation sequencing kit (highest yield).

Rapid barcoding (low-medium yield protocol)

Barcoding

1004

1005

1007

1006 1. Combine the following components per PCR tube:

Reagent	Volume (μL)
Debranched, cleaned	7.5
DNA (400 ng)	7.3
Fragmentation Mix	2.5
(RB01-12)	2.3
Total	10

1008 2. Mix the reagents by flicking the tube and spin briefly.

3. Incubate the samples at 30°C in a thermal cycler for 1 minute and 80°C for 1 minutes with 1009 heated lid off. 1010

4. Spin and pool all the rapid barcoded DNA in 1.5 mL Eppendorf DNA LoBind tube to make 1011 1012 1,200 ng in a volume of 50 μ L. Example, for 6 samples, take 200 ng (200 x 6 = 1,200 ng) 1013 DNA per sample.

- 1014 5. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.
- 1015 6. Add 25 μ L (0.5x) of resuspended beads to the sample and mix by flicking the tube multiple 1016 times.
- 1017 7. Incubate the tube for 5 minutes at room temperature.
- 1018 8. Spin down the sample and pellet on a magnetic rack/plate until the supernatant is clear 1019 and colourless. Keep the tube on the magnet, and carefully pipette off the supernatant.
- 1020 9. Wash the beads with 250 µl long Fragment Buffer (LFB) without touching/disturbing the 1021 pellet. Remove LFB carefully using a pipette and discard.
- 1022 Note* Flick the beads to resuspend, spin and put back on magnet and remove supernatant using a pipette. Long 1023 Fragment Buffer Expansion (EXP-LFB001) can be purchased separately from ONT.
- 10. Repeat the previous LFB washing step. 1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

11. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to dry for ~30 seconds, but do not dry the pellet to the point of cracking. 12. Remove the tube from the magnetic rack/plate and resuspend the pellet in 22 μL Elution Buffer (EB). Spin down briefly and incubate for 2 minutes at room temperature. 13. Pellet the beads on a magnetic rack/plate until the eluate is clear and colourless, for at least 1 minute. 14. Remove and retain 20 µL of eluate containing the DNA library into a clean 1.5 mL Eppendorf DNA LoBind tube. Rapid adapter ligation and loading 15. Quantify 1 µL rapid barcoded and cleaned DNA using a Qubit fluorometer. 16. Add 1 μL rapid adaptor (RAP) to 10 μL of barcoded DNA in EB in a PCR tube, flick multiple times to mix, spin briefly and incubate for 10 minutes at 20°C with the heated lid off. 17. Load 100 ng (51.36 fmol; considering 3kb product size) of final prepared library onto a flow cell following manufacturers recommendation.

Ligation sequencing (high yield protocol)

1051 End prep

1050

1053

1059

1052 1. Combine the following components per PCR tube:

Reagent	Volume (μL)
Ultra II End-prep reaction buffer	0.875
Ultra II End-prep enzyme mix	0.75
Debranched, cleaned DNA	12
Total	13.625

1054 2. Mix gently by flicking the tube, and spin down.

1055 Using a thermal cycler, incubate at 20°C for 5 minutes with heated lid off.

4. Incubate at 65°C for 5 minutes with heated lid on. 1056

1057 Native barcode ligation and cleanup

1058 5. Combine the following components per PCR tube:

Reagent	Volume (μL)
Native Barcode	1.25
Blunt/TA Ligase	6
Master Mix	
End prepped DNA	6
Total	13.25

- 6. Mix gently by flicking the tube, and spin down. 1060
- 1061 7. Incubate the reaction for 10 minutes at 20°C with heated lid off.
- 1062 8. Resuspend the AMPure XP beads by vortexing.
- 1063 9. Add 13.25 μL of resuspended AMPure XP beads to the reaction and mix by pipetting.
- 1064 10. Incubate for 5 minutes at room temperature.
- 1065 11. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the 1066 tube on the magnet, and pipette off the supernatant.
- 1067 12. Keep the tube on the magnet and wash the beads with 200 μL of freshly prepared 70% ethanol 1068 without disturbing the pellet. Remove the ethanol using a pipette and discard.

- 1069 13. Repeat the previous step.
- 1070 14. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to
- 1071 dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1072 15. Remove the tube from the magnetic plate and resuspend pellet in 15 μL nuclease-free water.
- 1073 Incubate for 2 min at room temperature.
- 1074 16. Pellet the beads on a magnet until the eluate is clear and colourless.
- 17. Remove and retain 12 μL of eluate into a clean PCR tube. 1075
- 1076 Measure DNA concentration with Qubit and pool all the barcoded DNA in 1.5 mL Eppendorf DNA
- 1077 LoBind tube to make 350 ng in a volume of 30 µL H2O. Example, for 6 samples, take 58.33 ng (58.33 x
- 1078 6 = 350 ng) DNA per sample.

1079

1080

1081

Adapter ligation and cleanup and loading

18. Combine the following components:

Reagent	Volume (μL)
Pooled barcoded DNA (350 ng)	30
Adapter Mix II (AMII)	5
Ligation Buffer (LNB)	10
Quick T4 DNA Ligase	5
Total	50

- 1082 19. Ensure the components are thoroughly mixed by pipetting, and spin down.
- 1083 20. Incubate the reaction for 15 minutes at 20°C.
- 1084 21. Resuspend the AMPure XP beads by vortexing.
- 1085 22. Add 25 µL (0.5x) of resuspended AMPure XP beads to the reaction and mix by pipetting.
- 1086 23. Incubate for 5 minutes at room temperature.
- 24. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the 1087
- 1088 tube on the magnet, and pipette off the supernatant.
- 1089 25. Wash the beads by adding 250 μl long Fragment Buffer (LFB).
- 1090 Note* Do not flick the beads to resuspend. Just gently wash and remove the supernatant using a 1091 pipette and discard.
- 1092 26. Repeat the previous step.
- 1093 27. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to
- 1094 dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1095 28. Remove the tube from the magnetic rack and resuspend the pellet in 17 μL Elution Buffer (EB).
- 1096 Spin down and incubate for 2 minutes at room temperature.

1097 29. Pellet the beads on a magnet until the eluate is clear and colourless, for at least 1 minute. 30. Remove and retain 15 μ L of eluate containing the DNA library into a clean 1.5 mL Eppendorf DNA 1098 1099 LoBind tube. 1100 31. Quantify 1 µL of adapter ligated and barcoded DNA using a Qubit fluorometer. 1101 32. Load 100 ng (51.36 fmol; considering 3kb) of final prepared library onto a flow cell following 1102 manufacturers recommendation. 1103 Note* The typical library size after this stage is around 3 kb. However, users can verify this by running the library 1104 on a gel or TapeStation for a few batches. Once the average expected library size is determined (sample or site-1105 wise), there will be no need to repeat this for every batch of samples. 1106 For loading sequencing library or washing flow cells, follow the manufacturers recommended

1107

protocols.